These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 27449147)

  • 1. Prevention of Meningococcal Infection in the United States: Current Recommendations and Future Considerations.
    Baker CJ
    J Adolesc Health; 2016 Aug; 59(2 Suppl):S29-37. PubMed ID: 27449147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Cohn AC; MacNeil JR; Clark TA; Ortega-Sanchez IR; Briere EZ; Meissner HC; Baker CJ; Messonnier NE;
    MMWR Recomm Rep; 2013 Mar; 62(RR-2):1-28. PubMed ID: 23515099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects for vaccine prevention of meningococcal infection.
    Harrison LH
    Clin Microbiol Rev; 2006 Jan; 19(1):142-64. PubMed ID: 16418528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving meningococcal immunization strategies.
    Sáfadi MA; Bettinger JA; Maturana GM; Enwere G; Borrow R;
    Expert Rev Vaccines; 2015 Apr; 14(4):505-17. PubMed ID: 25494168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults.
    Pace D
    Future Microbiol; 2010 Nov; 5(11):1629-40. PubMed ID: 21133685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
    Cohen R; Levy C
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. History of Meningococcal Outbreaks in the United States: Implications for Vaccination and Disease Prevention.
    Atkinson B; Gandhi A; Balmer P
    Pharmacotherapy; 2016 Aug; 36(8):880-92. PubMed ID: 27332671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States.
    Lingappa JR; Rosenstein N; Zell ER; Shutt KA; Schuchat A; Perkins BA;
    Vaccine; 2001 Aug; 19(31):4566-75. PubMed ID: 11483285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.
    Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT
    Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Epidemiology and Trends in Meningococcal Disease-United States, 1996-2015.
    MacNeil JR; Blain AE; Wang X; Cohn AC
    Clin Infect Dis; 2018 Apr; 66(8):1276-1281. PubMed ID: 29126310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
    Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meningococcal vaccination in pregnancy.
    Abu Raya B; Sadarangani M
    Hum Vaccin Immunother; 2018 May; 14(5):1188-1196. PubMed ID: 29485347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serogroup A meningococcal conjugate vaccines in Africa.
    Kristiansen PA; Jørgensen HJ; Caugant DA
    Expert Rev Vaccines; 2015; 14(11):1441-58. PubMed ID: 26358167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines.
    Villena R; Safadi MAP; Valenzuela MT; Torres JP; Finn A; O'Ryan M
    Hum Vaccin Immunother; 2018 May; 14(5):1042-1057. PubMed ID: 29667483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines.
    Pelton SI
    J Adolesc Health; 2016 Aug; 59(2 Suppl):S3-S11. PubMed ID: 27449148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges.
    Mustapha MM; Harrison LH
    Hum Vaccin Immunother; 2018 May; 14(5):1107-1115. PubMed ID: 29211624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meningococcal vaccine evolution.
    Bona G; Guidi C
    J Prev Med Hyg; 2012 Sep; 53(3):131-5. PubMed ID: 23362617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quadrivalent meningococcal conjugate vaccines.
    Pace D; Pollard AJ; Messonier NE
    Vaccine; 2009 Jun; 27 Suppl 2():B30-41. PubMed ID: 19477560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.